Non-nucleoside reverse transcriptase inhibitors
US6420359B1 · kind B1 · utility
5Cited by
2References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 12, 2001 |
| Grant date | Jul 16, 2002 |
| Priority date | — |
| Expiry date | Jun 12, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are compounds of the general formula I: whereinR2 is selected from the group consisting of H, F, Cl, (C1-4) alkyl, (C3-4) cycloalkyl and CF3; R4 is H or Me; R5 is H, Me or Et, with the proviso that R4 and R5 are not both Me, and if R4 is Me then R5 cannot be Et; R11 is Et, cyclopropyl, propyl, isopropyl, or isobutyl; andQ is selected from the group consisting of: and pharmaceutically acceptable salts thereof, as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.